The thesis

Zimmer Biomet Holdings designs and manufactures orthopedic products with a gross margin of 70.03% and revenue growth of 9.3% YoY. The company has a conviction score of 41/100, indicating a neutral outlook. With a P/E ratio of 24.8x and a net margin of 9.05%, the valuation appears reasonable. The analyst consensus rating is hold, suggesting a stable but unexciting outlook.

Why now

The current macro context, including China's chip tool push and the US-China squeeze, creates uncertainty for the company's supply chain and growth prospects. The recent decline in America's oil reserves to a 43-year low amidst a Middle East war adds to the economic uncertainty, making it essential to monitor ZBH's performance.

What to watch

The company's revenue growth and gross margin over the next two quarters will be crucial indicators of its ability to navigate the current macro environment. Investors should also monitor the analyst consensus rating and conviction score for any changes, which could signal a shift in the company's outlook.

Key risks

Valuation risk is a concern, as the P/E ratio of 24.8x may be high if revenue growth slows down. Execution risk is also present, as the company needs to maintain its gross margin and revenue growth in a challenging macro environment. Additionally, competitive risk from other orthopedic product manufacturers poses a threat to ZBH's market share.